An alternative set of metrics for the UK’s pricing and access dealLeela Barham takes a look at alternative ways pharma and the UK government could measure progress for the Share XAn alternative set of metrics for the UK’s pricing and access dealhttps://pharmaphorum.com/views-and-analysis/an-alternative-set-of-metrics-for-the-uks-pricing-and-access-deal/
Secret US-UK talks on drug pricing revealedDespite the UK still not leaving the European Union – pencilled in for the 31 January 2020 at Share XSecret US-UK talks on drug pricing revealedhttps://pharmaphorum.com/views-analysis-market-access/secret-us-uk-talks-on-drug-pricing-revealed/
Nice numbers at 20: what end-of-life evidence does NICE draw on?NICE may be 20 this year, but its policy on end-of-life (EoL) treatments – where NICE can recommend Share XNice numbers at 20: what end-of-life evidence does NICE draw on?https://pharmaphorum.com/views-analysis-market-access/nice-numbers-at-20-what-end-of-life-evidence-does-nice-draw-on/
NICE numbers at 20: trends in dealsNICE provides a downloadable excel file of details of Technology Appraisal (TAs) recommendations which can help explore trends Share XNICE numbers at 20: trends in dealshttps://pharmaphorum.com/views-analysis-market-access/nice-numbers-at-20-trends-in-deals/
NICE numbers at 20 – a closer look at cancerThere has been continual interest in what the UK’s Health Technology Assessment (HTA) agency, the National Institute for Share XNICE numbers at 20 – a closer look at cancerhttps://pharmaphorum.com/views-analysis-market-access/nice-numbers-at-20-a-closer-look-at-cancer/
NICE’s track record in cancer drugs: the impact of the CDF and interim fundingLeela Barham looks back to before the Cancer Drugs Fund and how recommendations have changed through CDF 1.0 Share XNICE’s track record in cancer drugs: the impact of the CDF and interim fundinghttps://pharmaphorum.com/views-and-analysis/nices-track-record-in-cancer-drugs-the-impact-of-the-cdf-and-interim-funding/
NICE numbers at 20Leela Barham takes a look at NICE’s stats on Technology Appraisals to see how the agency has changed Share XNICE numbers at 20https://pharmaphorum.com/views-analysis-market-access/nice-numbers-20/
VPAS 2024: What should industry consider next time?The UK pharmaceutical industry is just getting to grips with working under two new approaches to regulating branded Share XVPAS 2024: What should industry consider next time?https://pharmaphorum.com/views-analysis-market-access/vpas-2024-what-should-industry-consider-next-time/
Keeping up the PACE at the Scottish Medicines Consortium (SMC)There are many ways that patient centricity could be delivered when doing a health technology assessment (HTA). The Share XKeeping up the PACE at the Scottish Medicines Consortium (SMC)https://pharmaphorum.com/views-analysis-market-access/keeping-up-the-pace-at-the-scottish-medicines-consortium-smc/
